Evidence map›Paper›PMID 33495835›Full record

ArticleMolecular medicine reports2021

Cytotoxic effect of CLL‑1 CAR‑T cell immunotherapy with PD‑1 silencing on relapsed/refractory acute myeloid leukemia.

Guoqiang Lin, Yanming Zhang, Lei Yu, Depei Wu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?Hematology. American Society of Hematology. Education Program · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Guoqiang Lin *National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Yanming Zhang *Department of Hematology, Huai'an Hospital Affiliated to Xuzhou Medical College, Huai'an Second People's Hospital, Huai'an, Jiangsu 223002, P.R. China.
Lei YuInstitute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200065, P.R. China.
Depei WuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
East China Normal University · CNFirst Affiliated Hospital of Soochow University · CNSecond People’s Hospital of Huai’an · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The activation of chimeric antigen receptor (CAR)‑T cells can lead to persistently high levels of programmed cell death 1 (PD‑1) antigen and eventually causes the exhaustion of T cells. The effectiveness of CAR‑T cells targeting C‑type lectin‑like molecule‑1 (CLL‑1) combined with PD‑1 silencing therapy for acute myeloid leukemia (AML) was evaluated in the present study. CLL‑1 levels in primary AML bone marrow samples was examined using flow cytometric analysis. We designed a CLL‑1 CAR‑T, containing CLL‑1‑specific single‑chain variable fragment, CD28, OX40, CD8 hinge and TM and CD3‑ζ signaling domains. CLL‑1 CAR‑T with PD‑1 silencing was constructed. It was confirmed that CLL‑1 is expressed on the surface of AML cells. CLL‑1 CAR‑T showed specific lysing activity against CLL‑1

Indexed as

Adoptive TransferGene SilencingHumansK562 CellsLeukemia, Myeloid, AcuteProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenTHP-1 CellsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Chimeric Antigenacute myeloid leukemiaCD371chimeric antigen receptorC‑type lectin‑like molecule‑1programmed cell death 1

Identifiers

PMID33495835
PMCPMC7830996
OpenAlexW3124472806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.